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AbstrAct
Background Adolescents and young adults (AYAs) with 
cancer require dedicated management encompassing both 
adult and paediatric cancer services. Following a European 
survey, the European Society for Medical Oncology, the 
European Society for Paediatric Oncology and the Asian 
continental branch of International Society of Paediatric 
Oncology undertook a similar survey to assess AYA cancer 
care across Asia.
Methods A link to the online survey was sent to 
healthcare professionals (HCPs) in Asia interested in AYA 
cancer care. Questions covered the demographics and 
training of HCPs, their understanding of AYA definition, 
availability and access to specialised AYA services, the 
support and advice offered during and after treatment, and 
factors of treatment non-compliance.
Results We received 268 responses from 22 Asian 
countries. There was a striking variation in the definition 
of AYA (median lower age 15 years, median higher age 
29 years). The majority of the respondents (78%) did not 
have access to specialised cancer services and 73% 
were not aware of any research initiatives for AYA. Over 
two-thirds (69%) had the option to refer their patients for 
psychological and/or nutritional support and most advised 
their patients on a healthy lifestyle. Even so, 46% did not 
ask about smokeless tobacco habits and only half referred 
smokers to a smoking cessation service. Furthermore, 
29% did not promote human papillomavirus vaccination 
for girls and 17% did not promote hepatitis B virus 
vaccination for high-risk individuals. In terms of funding, 
69% reported governmental insurance coverage, although 
65% reported that patients self-paid, at least partially. 
Almost half (47%) reported treatment non-compliance or 
abandonment as an issue, attributed to financial and family 
problems (72%), loss of follow-up (74%) and seeking of 
alternative treatments (77%).
Conclusions Lack of access to and suboptimal delivery 
of AYA-specialised cancer care services across Asia pose 
major challenges and require specific interventions.
IntRoduCtIon
Cancer is not uncommon as a cause of 
morbidity and mortality among adolescents 
and young adults (AYAs) worldwide. The 
definition of AYA differs across countries 
and clinicians, but a recent authoritative 
review of epidemiology defined this group 
as patients aged between 15 and 39 years.1 
Cancer in this age group is less common than 
in older people; however, it is more common 
than in childhood: almost three times as 
many cancers occur in people aged 15–30 
years compared with younger individuals2; 
and a 2016 estimate suggested that around a 
million cases of cancer occurred globally in 
people aged 15–39.3
AYAs with cancer require dedicated care 
that encompasses aspects of both adult and 
Key questions
What is already known about this subject?
 ► Little was known about the training, practice and 
access to specialised resources of Asian health-
care providers in relation to care of adolescents and 
young adults (AYAs) with cancer.
What does this study add?
 ► This survey revealed important lack of access to 
specialised AYA cancer care in Asia. We hope that the 
current study will increase professional awareness 
on AYA-related issues across the Asian continent.
How might this impact on clinical practice?
 ► AYAs with cancer in Asia face special challenges 
regarding availability to AYA-dedicated cancer ser-
vices and evidence-based follow-up after treatment. 
We hope that our results represent a starting point 
to address issues like prevention, vaccination, prop-
er follow-up and healthy lifestyle maintenance after 
cancer treatment. Especially, raising the issue of 
treatment incompliance and abandonment among 
AYAs with cancer in Asia will help healthcare pro-
fessionals to identify potential causes and ways to 
tackle it. Ultimately, we hope that surveys like this 
will contribute to more focus on AYA cancer care that 
will improve professional and social awareness and 
will improve cancer care for this fragile and rather 
neglected patient group.
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paediatric services. Given improvements in survival in 
AYA patients with cancer and the relative low comorbid-
ities, a rapidly growing number of people have survived 
cancer diagnosed in adolescence and young adulthood. 
However, it is disturbing to note that survival rates in AYA 
with cancer have not improved to the same extent as in 
childhood cancer and in older adults.1 Paucity of clinical 
trials recruiting patients in this age group is one cause of 
this distressing situation.
The leading cancer types among AYAs differ from that 
in younger and older patients, and there are also differ-
ences both geographically and ethnologically. In a recent 
European series, the most frequent diagnoses were breast 
carcinoma (which accounts for 18% of cases), cutaneous 
melanoma (14%), germ cell tumours (13%), brain 
tumours (12%), carcinomas of the female genital tract 
(11%), thyroid cancer (7%), Hodgkin’s lymphoma (also 
7%) and non-Hodgkin’s lymphoma (6%).1 However, data 
from Cancer Incidence in Five Continents and SEER 
registries show that the incidence of testicular cancer in 
AYAs is markedly higher in Europe (137 cases per million) 
than in Asia (27 per million), with intermediate rates in 
North America (95 per million) and South and Central 
America (67 per million).4 It is likely that the incidence of 
other relevant tumours is also highly variable according 
to geography.
Moreover, differences in healthcare systems, AYA-dedi-
cated infrastructure, as well as cultural and social issues, 
lead to significant differences in AYA cancer care across 
the five continents. Hence, there is a need to collect data 
from individual regions and countries.
In 2016, the European Society for Medical Oncology 
(ESMO) and the European Society for Paediatric 
Oncology (SIOPE) conducted a European survey among 
clinicians with an interest in AYA oncology. Its results, 
published in 2017, revealed substantial underprovision of 
specialised services for AYA patients across Europe and 
marked differences in provision between geographical 
areas, with lack of access to those services being more 
pronounced in Eastern and Southeastern Europe than in 
Western and Northern regions.5
Following the successful paradigm of the European 
survey, ESMO and SIOPE in collaboration with the Asian 
continental branch of International Society of Paediatric 
Oncology (SIOP), SIOP Asia, conducted a similar survey 
in Asia. Through this survey, the three societies aimed to 
increase professional and social awareness on AYA-related 
issues across the multicultural and diverse Asian conti-
nent. Herein, we present the results of this survey empha-
sising on the special needs of young people with cancer 
across Asia.
MetHods
An online survey of 35 questions was conducted by the 
ESMO/SIOPE/SIOP Asia steering committee. Health-
care professionals (HCPs) who had declared a specific 
interest for AYA with cancer were identified through 
their national registries and/or the membership lists of 
the three societies and were invited via email to complete 
an online questionnaire on a voluntary and anonymous 
basis. The questionnaire obtained data on respondents’ 
demographic characteristics, their perception of the age 
definition of AYA, the services and clinical management 
they could provide, efforts to maintain the health of AYA 
survivors after cancer treatment, cancer risk assessment 
and management, educational activities available to HCPs 
interested in the AYA field, and means of raising aware-
ness and improving care and outcome. The question-
naire was based largely on that used in the prior Euro-
pean survey but was adapted to take into account of issues 
that are relevant to some Asian countries, including the 
healthcare setting (urban vs rural), routine performance 
of pretreatment counselling of the patient and her/his 
family regarding adverse/late side effects of treatment 
and especially fertility, particular habits (ie, smokeless 
tobacco chewing), promotion of hepatitis B vaccination 
for AYA patients with high risk of exposure to hepatitis 
B virus, access to nutritionist/dietician and treatment 
non-compliance or abandonment for a variety of reasons. 
A section on the availability of health insurance or other 
means of payment for care and reasons for treatment 
discontinuation was also included. The full questionnaire 
was available online at www. esmo. org and provided in 
online supplementary file 1.
Results
Characteristics of respondents
There were a total of 268 respondents: 39% female and 
61% male.
The age distribution was as follows: 20–29 years, 5%; 
30–39 years, 38%; 40–49 years, 32%; 50–59 years, 19%; 60 
years and over 7%. Altogether, 22 countries were repre-
sented (figure 1). The great majority of respondents 
were from the South and the Southeast Asia; only 5% of 
respondents were from the Middle East. In country of 
origin, the largest proportion (19%) came from Japan, 
followed by India (17%), China (14%) and the Republic 
of Korea (10%). Given the non-proportional distribution 
of respondents, we have not analysed data by country or 
geographical subregion.
The majority (93%) of respondents serve in urban areas 
and only 7% in rural areas. Half were medical oncologists 
and 26% paediatric oncologists, with 7% being radiation 
oncologists, 3% haematologists and 3% surgical oncolo-
gists. Four per cent were in training. Very few responses 
from nurses (0.4%) were received.
The majority of respondents to the Asian survey (52%) 
worked in general academic centres, with 21% in special-
ised cancer hospitals, 18% in general hospitals and 10% 
in paediatric or children’s hospitals.
Fifty per cent had been trained to treat adult patients 
with cancer, 28% to treat paediatric cases and 22% both. 
In Europe, 60% had been trained to treat adults, 25% 
paediatric patients and 15% both.
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Figure 1 Country representation of the respondents.
There were wide differences in the number of patients 
aged 15–39 years Asian respondents had treated over 
the past year. Thirty-five per cent had treated between 1 
and 10 such patients, 23% had treated 11–20, 18% had 
treated between 21 and 50 cases, and 19% more than fifty. 
Six per cent had treated none.
Management of AYA patients and access to services
Respondents were asked about their perception of the 
AYA age range. The mean lower age limit was reported 
to be 15 years (median 15; range 10–25) and the mean 
upper limit 29 years (median 30; range 15–39).
Respondents were presented with three hypothetical 
patients (all aged 17 years)—who had metastatic soft-
tissue sarcoma, acute lymphoblastic leukaemia (ALL) or 
embryonal carcinoma of the testis—and asked whether 
(in their country) the doctor leading patient manage-
ment would be trained in adult oncology, paediatric 
oncology or both (figure 2). In sarcoma, it was thought 
the physician would be more likely to have adult rather 
than paediatric training (39% vs 23%). With testicular 
carcinoma, 44% thought the responsible physician would 
be adult trained versus 24% paediatric trained. Only with 
ALL, did the more respondents think the treating physi-
cian should be paediatric rather than adult trained (34% 
vs 31%).
When asked if their patients could access specialised 
services for AYA with cancer in which adult and paedi-
atric specialists worked together, or if such services were 
in development, 78% of respondents said they cannot. 
Fifteen (15%) of respondents reported that such services 
were available.
Respondents were asked whether AYAs whom they 
treated had access to a range of professionals with expe-
rience in AYA cancer (figure 3). The majority (>60%) 
reported that their patients had access to the support of 
a professional psychologist, social worker, physiotherapist 
or occupational therapist and nutritionist or dietician. 
However, less than half had access to a mentor to guide 
their education or training (37%) and to a support group 
of other young people (43%). Finally, 28% had access to 
age-specific specialised nursing.
When respondents were asked whether they were 
aware of the trends in outcome for AYAs compared with 
those for children or older adults with cancer, 63% said 
they were not. Seventy-three per cent were not aware of 
research initiatives, clinical trials or studies (near them or 
further afield) focused on the specific clinical, epidemio-
logical or psychosocial features of AYAs with cancer.
Promoting well-being and preventing disease among AYA 
cancer survivors
Asked if they routinely undertook pretreatment counsel-
ling of the patient and her/his family regarding adverse 
and late effects of treatment, and especially fertility, 69% 
said they do it regularly. Less than half (42%) reported 
that their institutions offer consultation with a fertility 
specialist to help meet their wish to children after treat-
ment.
Seventy-seven per cent reported that patients who had 
had potentially cardiotoxic treatment were evaluated for 
modifiable cardiovascular risk factors such as high blood 
pressure, high cholesterol and obesity.
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Figure 2 Responses to the question ‘What is the most likely training background for the doctor leading the treatment of a 
17-year-old patient with soft-tissue sarcoma, acute lymphoblastic leukaemia and metastatic embryonal carcinoma of testis in 
your country?’
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Figure 3 Responses to the question ‘Please indicate whether adolescents and young adults (AYAs) whom you treat have 
access to any of the following professionals with experience in AYA cancer’
The majority of patients (approximately 80%) were 
advised on the importance of a healthy approach to body 
weight, eating healthily and remaining active. Sixty-seven 
per cent of respondents advised patients to cut back on 
alcohol consumption and 52% gave advice on limiting 
exposure to the sun (figure 4). Advice on tobacco-re-
lated habits is considered in table 1, which provides a 
summary of situation where we received an answer from 
the respondents.
Respondents were also asked if they had access to a 
specialised service to advise AYA patients some years after 
treatment on late effects. Fifty-nine per cent did not. 
Fewer than a third of respondents overall (27%) had 
access to a specialised service to which they could refer 
patients some years after completion of cancer treatment. 
This service was envisaged as providing education and 
minimising the risk of late effects or enhancing their 
management.
In relation to vaccination in general, respondents were 
asked how often they reviewed the status of AYA patients 
after cancer to ensure they complied with national stan-
dards. Seventeen per cent admitted that they never did 
this. Nine per cent reviewed vaccination status at each 
visit, 43% occasionally and 18% annually. More specif-
ically, 58% of respondents promoted human papillo-
mavirus (HPV) vaccination for young female patients, 
though 29% did not. Fourteen per cent recommended 
HPV vaccination for young male patients with cancer. 
Seventy per cent promoted vaccination against hepatitis 
B for those patients at risk while 17% did not.
Family history
Sixty-five per cent of respondents said they felt competent 
to evaluate family history and to screen AYA patients for 
the more frequent hereditary syndromes that predispose 
to cancer. In total, 56% had access to a genetics service for 
AYA patients with a family history that suggested a hered-
itary cancer syndrome.
Improving the AYA cancer care service
Thirty-five per cent of respondents said that their unit, 
hospital, region or country asked AYA patients about 
the quality of their care as part of an effort to improve 
services. Forty-seven per cent said their patients were not 
consulted in this way.
Only 12% of respondents said they had access to educa-
tion and training courses (online or face to face) that 
were focused on the management of AYAs with cancer. 
Sixty-nine per cent said that they did not. In relation to 
educational activities that ESMO/SIOPE Joint Working 
Group on AYA in Cancer might undertake in the future, 
respondents were asked to prioritise four options. Cancer 
treatment services and their quality improvement for AYA 
was given top priority by 47% of respondents. Survivor-
ship health for AYA after cancer was prioritised by 28%; 
basic science and clinical research about AYA cancer by 
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Figure 4 Responses to the question ‘Do you choose to discuss with AYA patients the issues related to each of the following 
lifestyle factors after their cancer treatment?’ AYA, adolescents and young adult.
Table 1 Health advice in relation to tobacco use: 
proportion of respondents
No Yes
Asking patients about smoking habit at 
every visit
33% 54%
Advising patients who smoke to stop 6% 81%
Suggesting referral to a smoking cessation 
service
38% 49%
Planning follow-up in regard to tobacco 
use
52% 35%
Asking about use of smokeless (eg, 
chewing) tobacco
46% 40%
27%; and cancer risk assessment and cancer prevention 
in AYA by 22%.
Funding for and compliance with treatment
The Asian survey, unlike the survey conducted earlier 
in Europe, asked about the sources of funding for care 
in AYA cancer. It seems that several funding sources 
are involved (figure 5). Around two-thirds of respond-
ents acknowledged government-based social insurance, 
as well as patient self-funding. Private insurance plays a 
part for around 56%. Fifty per cent of respondents said 
charities are a source and 20% industry. In response to a 
further question, 56% said that they did not experience 
particular difficulties in terms of insurance for their AYA 
patients while 26% said that they did.
Respondents were asked whether lack of compliance or 
treatment discontinuation was an issue for their patients. 
Almost half of the respondents (47%) said that it was. 
These respondents were then asked a further question, 
about the proportion of their patients at risk. Almost 
half (47%) said that it was an issue for 10% or fewer of 
their patients, and a further 30% that it was an issue in 
10%–30%. However, 9% of respondents who thought 
that failure to comply with or complete treatment was an 
issue in AYA cancer reported that it affected more than 
half of their patients.
Financial problems and/or lack of insurance coverage, 
family issues and lack of belief in the benefits of treatment 
(possibly accompanied by seeking alternative treatments) 
were all thought to play a substantial role in this failure 
to adhere to or complete treatment (table 2). Religious 
beliefs were thought relevant by 27% of respondents. 
Notably, three-quarters of respondents thought that loss 
to follow-up was an important issue for their patients.
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Figure 5 Responses to the question ‘where does the insurance cover for your patients come from?’
Table 2 Reasons for lack of compliance with or 
abandoning treatment
No Yes
Financial problems/lack of insurance cover 28% 72%
Family problems 28% 72%
Disbelief in treatment benefit/seeking 
alternatives
23% 77%
Religious reasons 73% 27%
Loss to follow-up 26% 74%
Finally, gender discrimination was an issue in a fami-
ly’s decision to treat the AYA patient, for one out of four 
respondents (24%).
dIsCussIon
There is increasing recognition that the needs of 
patients with cancer differ according to the site of 
the primary tumour, extent of spread and molecular 
biology, and according to the individual patient charac-
teristics. One major such factor is age at diagnosis.
The care of elderly patients is likely to be complicated 
by frailty, comorbidities and polypharmacy—and that it 
needs to be modulated according to competing causes 
of mortality and life expectancy. The care of AYAs with 
cancer is in many respects the other side of the coin: 
setting the cancer to one side, AYAs are likely to be in 
good health, with robust physiological reserves, and have 
a long life expectancy. But they also face particular issues 
relating to social, psychological and cognitive function, 
maintenance of fertility, and the possibility of long-term 
adverse events associated with treatment. For example, 
Keegan et al found that AYAs with a second malignant 
tumour—Hodgkin lymphoma, sarcoma, breast, thyroid 
or testicular cancer—were more than twice as likely to 
die of their disease than those with the same tumour but 
no prior cancer.6 This may explain why survival in AYAs 
with cancer has not improved as much as survival in older 
people with the same tumours. Other potential contrib-
uting factors include different tumour biology, including 
genomic risk, histopathology and response to chemo-
therapy.7 However, it is also possible that the relatively 
poor outcome is due at least in part to the fact that AYAs 
fall into the age group that is neither paediatric nor main-
stream adult oncology and may, as a result, have received 
services that are not adapted to their needs, along with 
insufficient clinical trial inclusion. Both these problems 
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may explain the poor improvement in survival. Relevant 
to the latter point, it is striking that in many countries the 
AYA age group is an increasingly large proportion of the 
total population. In Bangladesh, for example, it accounts 
for 44% of the nation.8
It is in this context that the ESMO/SIOPE/SIOP 
Asia survey was conducted. It had the aim not only 
of obtaining information about access to specialised 
services for AYA patients, but to raise awareness for 
research and education. Overall, respondents from Asia 
had considerably less access to specialised AYA services 
combining paediatric and adult oncology expertise than 
their European counterparts: 15% had such access, 
compared with 33% in Europe. That said, the majority 
were able to refer patients for specialised psychological 
support and had access to social workers—both profes-
sions being important to patients in whom the psycho-
social impact of cancer is enormous. However, AYA 
patients in Asia had considerably less access to other 
specialised services, including genetic counselling, 
nutritional support, smoking cessation services and 
fertility preservation counselling compared with their 
European counterparts.
The survey revealed some particular aspects that need 
to draw our attention especially to Asian AYA patients: 
First, there is a striking underprovision of care in rural 
areas; second, AYAs with ‘paediatric type’ malignancies 
(ie, rhabdomyosarcoma) tend to be treated by adult 
oncologists, perhaps due to the relative paucity of paedi-
atric oncologists in Asian countries; third, hazardous 
habits, like chewing smokeless tobacco, are popular in 
some Asian countries; fourth, consultation regarding 
late effects, vaccination and healthy lifestyle is lagging 
behind to that in Europe; and finally and perhaps more 
strikingly, the levels of treatment non-compliance and 
abandonment due to financial, social and cultural 
issues, including gender discrimination are worri-
some and call for specific, cause-related interventions, 
including proper education and information for the 
family and the caregivers.
What are the needs of the HCPs taking care of AYAs 
with cancer in Asia? Respondents identified monitoring 
post-treatment, communication with professionals, 
preservation of fertility and return to work and school 
as priorities in care, similar to the European survey.9 
In relation to the scope for future initiatives, only 12% 
of respondents said they currently had access to educa-
tion and training focused on AYA cancer management, 
and almost half gave a top priority to courses that could 
potentially improve the quality of care for their AYA 
patients. There is clearly an urgent need to provide 
education and training to these HCPs and this gives 
a clear lead to professional bodies willing and able to 
provide such material and services. International collab-
orations among societies like ESMO, SIOPE and SIOP 
Asia set the example for such fruitful collaboration.
We noticed a range of differences in terms of our previ-
ously conducted European landscape in AYA cancer 
care. The high proportion of male respondents in the 
Asian survey contrasts with that in European one where 
the majority of those who completed the questionnaire 
were female. The proportion of European respondents 
who reported they could access the specialised services 
for AYA with cancer is at some extent better: 33% overall, 
arising to 60% in Northern Europe. The figures about 
access to a range of different professionals with experi-
ence in AYA cancers are around 10% lower in Asia than 
that reported in earlier European survey. There are 
also considerable differences among Asian and Euro-
pean respondents in terms of whether their institutions 
offer consultation with a fertility specialist to help meet 
their wish to children after treatment (42% vs 62%) or 
evaluation for modifiable cardiovascular risk factors in 
patients who had had potentially cardiotoxic treatment 
(77% vs 91%). Finally, the access to a genetics service 
for AYA patients with a family history that suggested 
a hereditary cancer syndrome is substantially less in 
Asia (56%) than that among respondents from both 
Northern Europe (95%) and Southern Europe (81%).
The Asian survey was not a random sample of Asian 
clinicians who treat AYA cancer patients. The majority 
of respondents came from only four countries: Japan, 
India, China and the Republic of Korea. This represents 
one of the major limitations of the survey when consider 
the great heterogeneity across Asian countries, and 
therefore, the results cannot be interpreted as repre-
sentative of the whole Asian continent. Importantly, 
all but 7% practised in urban areas, meaning that in 
the current survey, there is an under-representation of 
the AYA cancer care in rural Asia. Further limitations 
are the relatively small number of overall responses 
(although we are not aware of current Asian workforce 
in the AYA oncology field) and that respondents were 
drawn from a wide range of age groups and a spread 
of specialties and training backgrounds. Moreover, the 
fact that the respondents were self-selected introduces 
an inherent and largely unavoidable bias to our survey, 
since respondents had declared a personal interest in 
AYA cancer care and were thus more likely to reply to 
the questionnaire.
Nevertheless, our survey represents a starting point to 
better understand the current situation in AYA cancer 
care in Asia. More importantly, we hope that our results 
will increase professional and social awareness on issues 
like prevention, vaccination, early diagnosis and main-
taining a healthy lifestyle among AYA cancer survivors. 
Last but not least, raising the issue of treatment incom-
pliance and abandonment will help HCPs to identify 
potential causes and ways to tackle the problem. Ulti-
mately, we hope that surveys like this will contribute to 
focus more on AYA and improve cancer care for this 
fragile and rather neglected patient group.
In conclusion, our survey among Asian HCPs 
providing care to AYA patients with cancer revealed a 
substantial lack of access and suboptimal delivery of 
AYA-dedicated cancer care across Asian countries. Lack 
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of infrastructure and specialised services for AYA, as 
well as of AYA-orientated education and training pose 
major challenges and worrisome levels of treatment 
non-compliance and abandonment call for cause-spe-
cific interventions.
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